Biorestorative Therapies shares rise 3.40% intraday after reporting Q2 2025 financial results and clinical program milestones.

Biorestorative Therapies, Inc. rose 3.40% in intraday trading, with the company reporting its second-quarter 2025 financial results and providing an update on its business. The company's CEO, Lance Alstodt, highlighted the achievement of key clinical program milestones and the company's focus on executing its growth strategy while managing resources.